Mode
Text Size
Log in / Sign up
N/A Completed N=980

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)

Post Menopausal Women With Early Breast Cancer
Source: ClinicalTrials.gov NCT01050634 ↗
Enrolled (actual)
980
Serious AEs
1.2%
Results posted
Jul 2010
Primary outcomePrimary: Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores — -5.82; -8.37; -8.22; -7.04 mm

Summary

Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire. Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane). Deeper knowledge of Adverse Events during routine administration.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores
-5.82; -8.37; -8.22; -7.04; -5.98; -2.06 —
PRIMARY
Change From Baseline in Thickness of Endometrium
-1.1 —
PRIMARY
Change From Baseline in IBCSG LASA Items Scores - QoL Module 24-26
-5.22; -7.44; -3.45; -4.98; -1.70; -5.35 —
PRIMARY
Change From Baseline in 12-Item Short Form Health Survey (SF-12) Summary Subscales (Physical Summary Scale Derived From Items 1-5, 8 and Mental Summary Scale Derived From Items 6, 7, 9-11) Scores
2.93; 2.02 —
PRIMARY
Change From Baseline in IBCSG Vaginal Symptoms - QoL Module 24-26
-10.2 —

Eligibility Criteria

Inclusion Criteria

  • Early Breast Cancer, post-menopausal, 2-3 yrs adjuvant tamoxifen therapy.

Exclusion Criteria

  • Not applicable.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01050634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search